BIOGEN MA

BIOGEN MA is a leading global biotechnology company that has pioneered several groundbreaking innovations, including a broad portfolio of treatments for multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed therapies targeting the definitive pathology of Alzheimer's disease. Biogen is advancing a range of potential new therapies across neurology, neuropsychiatry, specialized immunology, and rare diseases, with an unwavering focus on serving humanity through science while promoting a healthier, more sustainable, and equitable world.